Msm8.5

MSM

Methylsulfonylmethane

Sulfur compound that supports joint health, reduces inflammation, and may improve exercise recovery.

immunityrecoveryjoint healthsulfurinflammationrecovery
Last reviewed: January 1, 2025
8.5/10
40+ studies
Evidence
high
Safety
2-3g
Dose
4-12 weeks
Time to Effect
Powder or capsules
Best Form

MSM is an organic sulfur compound found naturally in some foods and the human body. Sulfur is essential for connective tissue, and MSM is commonly used for joint pain, inflammation, and exercise recovery. Often combined with glucosamine and chondroitin for comprehensive joint support.

Mechanisms of Action

🔬
Sulfur Donor

Provides sulfur for connective tissue

🔥
Anti-Inflammatory

Reduces inflammatory signaling

Recommended Dose

2-3g

1000mg6000mg

Optimal Timing

  • With meals
  • Split into 2-3 doses

Take with food

Best Form

Powder or capsules

Alternatives: Crystals, Combined with glucosamine/chondroitin

OptiMSM is a purified, well-tested form. Powder is cost-effective for higher doses.

Duration

Minimum: 4 weeks

Optimal: 12 weeks

Cycling: Not required

Note: Taking with food may reduce GI upset. Can be taken as single dose or divided.

Personalized Dosage Calculator

Get a dosage recommendation tailored to your body weight, age, goals, and health profile.

Set up your health profile for personalized recommendations

🦵
Joint Pain Relief

Reduced joint pain and improved function

4-12 weeks
60% of users notice thispositive
💪
Reduced Muscle Soreness

Less post-exercise soreness

2-4 weeks
55% of users notice thispositive
✨
Hair, Skin, Nails

May improve keratin-rich tissues

8-12 weeks
45% of users notice thispositive
High SafetyMax safe dose: Up to 6g/day shown safe
🔴
Pregnant/nursing

Insufficient data; avoid unless advised by doctor

Who Should NOT Take This

  • Known allergy or hypersensitivity to MSM or related compounds

Drug Interactions

Blood thinnersmild

May have mild anticoagulant effects — may affect platelet aggregation or vitamin K-dependent clotting factors, altering anticoagulant efficacy

Possible Side Effects

GI upsetuncommon

Tip: Take with food; start with lower dose

Headacherare

Tip: Usually resolves; reduce dose

Insomniarare

Tip: Take earlier in day

Warnings

  • May take several weeks to see joint benefits
  • Quality varies — look for OptiMSM or similar purified forms

Top studies from 40+ peer-reviewed papers

meta-analysisn=2455
DOI

Chen CS et al. • Journal of integrative medicine (2025)

“Passion fruit peel extract was the best supplement for improving WOMAC pain and function scores in patients with osteoarthritis, followed by Lanconone and collagen.”
Key Findings:
  • In the WOMAC pain score, the SUCRA of passion fruit peel extract was 91% (mean difference [MD]: -9.2; 95% confidence interval [CI]: [-16.0, -2.3]), followed by methylsulfonylmethane (89%), undenatured type II collagen (87%), collagen (84%), and Lanconone (82%).
  • The SUCRA (99%) of passion fruit peel extract (MD: -41.0; 95% CI: [-66.0, -16.0]) ranked first in terms of the WOMAC function score, followed by Lanconone (95%), collagen (86%), ParActin (84%), and Lactobacillus casei strain Shirota (83%).
  • The top three total rankings are passion fruit peel extract (95.0%), Lanconone (88.5%), and collagen (85.0%).
meta-analysisn=1766
DOI

Szondy I et al. • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2024)

“Doxy-PEP significantly reduces the number of new cases of chlamydia and syphilis and is potentially effective against gonorrhea, influenced by local resistance patterns.”
Key Findings:
  • The pooled analysis of 1,766 participants with 602 newly diagnosed STIs showed a 56% decrease in the overall STI incidence using doxy-PrEP/PEP (RR = 0.44; 95% CI: 0.30-0.65; I2 = 73%).
  • For doxy-PEP, including MSM and TGW only, the RR observed for overall STI incidence was 0.40 (95% CI: 0.28-0.57; I² = 37%), 0.19 (95% CI: 0.08-0.44; I² = 39%) for chlamydia, 0.23 (0.14-0.36; I² = 0%) for syphilis and 0.55 (95% CI: 0.34-0.87; I² = 41%) for gonorrhea.
  • Doxy-PEP significantly reduces the number of new cases of chlamydia and syphilis and is potentially effective against gonorrhea, influenced by local resistance patterns.
  • Thus, it is a promising tool in the prevention of bacterial STIs among MSM and TGW.
rctn=506
DOI

Vanbaelen T et al. • The lancet. HIV (2024)

“We failed to show that non-screening for N gonorrhoeae and C trachomatis is non-inferior to 3 × 3 screening in MSM and transgender women taking PrEP in Belgium.”
Key Findings:
  • We failed to show that non-screening for N gonorrhoeae and C trachomatis is non-inferior to 3 × 3 screening in MSM and transgender women taking PrEP in Belgium.
  • However, screening was associated with higher antibiotic consumption and had no effect on the incidence of N gonorrhoeae.
  • Further research is needed to assess the benefits and harms of N gonorrhoeae and C trachomatis screening in this population.
meta-analysisn=870
DOI

Perazzo H et al. • Journal of viral hepatitis (2023)

“Oral fluid HCVST should be considered in key populations for uptake HCV testing.© 2023 John Wiley & Sons Ltd.”
Key Findings:
  • The pooled estimate of agreement for re-reading was 95.0% [95% CI 91.5-97.6] (n = 831; I2  = 74.0%) and for re-testing was 94.4% [90.3-97.5] (n = 726; I2  = 77.1%).
  • The pooled estimate of those who would recommend HCVST was 94.4% [84.7-99.6] (n = 625; I2  = 93.7%).
  • Pooled estimates (95% CI) of correct sample collection (72.8% [63.3-81.5] vs. 90.8% [85.9-94.8]) and performance of HCVST without needing assistance (44.1% [14.1-76.7] vs. 78.1% [53.4-95.3]) was lower in PWID compared to MSM.
meta-analysisn=46
DOI

Stannah J et al. • The lancet. HIV (2023)

“HIV incidence remains high, and might not be decreasing among MSM in Africa over time, despite some increases in HIV testing and ART use.”
Key Findings:
  • HIV incidence remains high, and might not be decreasing among MSM in Africa over time, despite some increases in HIV testing and ART use.
  • Achieving the UNAIDS 95-95-95 targets for diagnosis, treatment, and viral suppression equitably for all requires renewed focus on this key population.
  • Combination interventions for MSM are urgently required to reduce disparities in HIV incidence and tackle the social, structural, and behavioural factors that make MSM vulnerable to HIV acquisition.
39
Total Studies
9.0/10
Avg Quality
22-34,740
Sample Size Range
2004-2025
Research Span

Study Type Distribution

Meta-Analysis
25
RCT
10
Systematic Review
3
Animal
1

This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.